Central Retinal Vein Occlusion Market: By Treatment (Anti-vascular Endothelial Growth Factor, Corticosteroid Drugs, Laser Retinal Photocoagulation, and Others), By Condition (Ischemic, Non-Ischemic), By Diagnosis (Optical Coherence Tomography, Fundoscopic Examination, Fluorescein Angiography, and Others), By End Users (Hospitals, Clinics, Research and Academics, Others) and Geography

Central Retinal Vein Occlusion Market was valued at USD 3.4 billion in 2022 and is poised to grow at a CAGR of 6.2% over 2023-2029. Central retinal vein occlusion (CRVO) is a condition in which the main vein that drains blood from the retina closes off partially or completely at or proximal to the lamina cribrosa of the optic nerve, where the central vein exists in the eye, causing blurred vision, and other eye problems. Based on the treatment type, Anti–vascular endothelial growth factor is anticipated to dominate the central retinal vein occlusion market share over the forecast period. According to a research report, globally, an estimated 2.5 million adults are affected by central retinal vein occlusion. The rise of ophthalmic disease with the increase in the elderly population will act as the central retinal vein occlusion market growth driver, whereas the high cost of treatment and side effects would be the restraining factor for the market. Investment by the market players in the treatment and diagnosis of the condition and in product development and expansion of product portfolios are opportunities for the expansion of the market.

Central Retinal Vein Occlusion Market Key Developments:

• In Feb 2023, Kodiak Sciences completed a phase-III BEACON trial in retinal vein occlusion in the USA, Czech Republic, France, Hungary, Israel, Italy, Latvia, Poland, and Others for KSI-301, an intravitreal injection.